Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02055716 | Sulforadex in Healthy Human Males MAD | completed | Phase 1 | 18 | Evgen PharmaINDUSTRY | 1 | Feb 10, 2015 | clinicaltrials |
| NCT00539968 | A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED) | terminated | Phase 1 / Phase 2 | 5 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 5, 2015 | clinicaltrials |
| NCT00631527 |
| Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer |
| completed |
| Phase 1 |
| 19 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Jan 29, 2015 |
| clinicaltrials |
| NCT00151086 | Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 33 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 22, 2015 | clinicaltrials |
| NCT00913263 | An Efficacy and Safety Study With Licroca Depot, a Controlled Release Product, Injected Into the Prostate(2-HOF) | completed | Phase 1 / Phase 2 | 24 | Lidds ABINDUSTRY | 1 | Jan 19, 2015 | clinicaltrials |
| NCT00511576 | Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors | terminated | Phase 1 | 54 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jan 8, 2015 | clinicaltrials |
| NCT01324583 | Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer | completed | Phase 1 | 48 | SanofiINDUSTRY | 1 | Jan 7, 2015 | clinicaltrials |
| NCT01497431 | Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants | completed | Phase 1 | 66 | National Cancer Institute (NCI)NIH | 1 | Nov 26, 2014 | clinicaltrials |
| NCT01610050 | A Phase I Study of LFA102 in Japanese Patients | completed | Phase 1 | 14 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 11, 2014 | clinicaltrials |
| NCT00753220 | Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer(CRITICAL) | terminated | Phase 1 / Phase 2 | 7 | Bostwick LaboratoriesINDUSTRY | 1 | Nov 4, 2014 | clinicaltrials |
| NCT01320787 | 18-F-Fluoroacetate as PET Imaging Agent | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Oct 23, 2014 | clinicaltrials |
| NCT01009736 | Effects of Tomato-Soy Juice on Biomarkers in Patients With Prostate Cancer Undergoing Prostatectomy | completed | Phase 1 / Phase 2 | 60 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Oct 16, 2014 | clinicaltrials |
| NCT01020305 | Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 5 | Sandy SrinivasOTHER | 1 | Oct 13, 2014 | clinicaltrials |
| NCT00459407 | Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate | completed | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2014 | clinicaltrials |
| NCT01902251 | Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients | completed | Phase 1 | 27 | Astellas Pharma Europe B.V.INDUSTRY | 1 | Sep 9, 2014 | clinicaltrials |
| NCT00323882 | Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 75 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 28, 2014 | clinicaltrials |
| NCT00005072 | Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer | terminated | Phase 1 / Phase 2 | 25 | VicalINDUSTRY | 1 | Jul 29, 2014 | clinicaltrials |
| NCT02054793 | Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC) | withdrawn | Phase 1 / Phase 2 | 0 | Emmanuel Antonarakis, MDOTHER | 1 | Jul 23, 2014 | clinicaltrials |
| NCT00424385 | Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC) | completed | Phase 1 | 17 | Oncology Specialists, S.C.OTHER | 1 | Jul 21, 2014 | clinicaltrials |
| NCT00313599 | Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 28 | University of California, San FranciscoOTHER | 1 | Jul 2, 2014 | clinicaltrials |
| NCT00305669 | GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer | completed | Phase 1 | 24 | University of California, San FranciscoOTHER | 1 | Jun 25, 2014 | clinicaltrials |
| NCT00748046 | Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton | completed | Phase 1 | 10 | BayerINDUSTRY | 1 | Jun 25, 2014 | clinicaltrials |
| NCT00058253 | Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2014 | clinicaltrials |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | terminated | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00002721 | Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | completed | Phase 1 | 18 | University of New MexicoOTHER | 1 | May 21, 2014 | clinicaltrials |
| NCT00519233 | AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer | completed | Phase 1 | 13 | Astellas Pharma IncINDUSTRY | 1 | May 2, 2014 | clinicaltrials |
| NCT00414388 | Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer | completed | Phase 1 / Phase 2 | 22 | Oncology Specialists, S.C.OTHER | 1 | Apr 7, 2014 | clinicaltrials |
| NCT00439270 | Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 49 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 28, 2014 | clinicaltrials |
| NCT00859729 | Dose Finding Study of a DNA Vaccine Delivered With Intradermal Electroporation in Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 15 | Uppsala UniversityOTHER | 1 | Mar 17, 2014 | clinicaltrials |
| NCT00890747 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2014 | clinicaltrials |
| NCT00770848 | AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 162 | AmgenINDUSTRY | 0 | Mar 10, 2014 | clinicaltrials |
| NCT00458731 | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma | completed | Phase 1 | 57 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2014 | clinicaltrials |
| NCT00808418 | A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer | completed | Phase 1 | 34 | Synta Pharmaceuticals Corp.INDUSTRY | 1 | Feb 3, 2014 | clinicaltrials |
| NCT00305747 | Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy | completed | Phase 1 | 12 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jan 15, 2014 | clinicaltrials |
| NCT00002775 | Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | unknown | Phase 1 / Phase 2 | 37 | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00003633 | Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer | unknown | Phase 1 | 12 | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT00024063 | SU006668 in Treating Patients With Advanced Solid Tumors | unknown | Phase 1 | — | Jonsson Comprehensive Cancer CenterOTHER | 0 | Dec 19, 2013 | clinicaltrials |
| NCT00433797 | Dietary Intervention With Phytochemicals and Polyunsaturated Fatty Acids in Prostate Cancer Patients | completed | Phase 1 / Phase 2 | 86 | University of OsloOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT02001571 | A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function | completed | Phase 1 | 24 | Cougar Biotechnology, Inc.INDUSTRY | 1 | Dec 5, 2013 | clinicaltrials |
| NCT00003183 | Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer | unknown | Phase 1 / Phase 2 | 64 | Hope Cancer Institute, Inc.INDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT01414296 | Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer | completed | Phase 1 | 10 | Progenics Pharmaceuticals, Inc.INDUSTRY | 1 | Nov 14, 2013 | clinicaltrials |
| NCT00005939 | Brachytherapy in Treating Patients With Recurrent Prostate Cancer | unknown | Phase 1 / Phase 2 | — | Center for Molecular MedicineOTHER | 1 | Nov 6, 2013 | clinicaltrials |
| NCT01414283 | Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer | completed | Phase 1 | 52 | Progenics Pharmaceuticals, Inc.INDUSTRY | 1 | Nov 1, 2013 | clinicaltrials |
| NCT00132522 | EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide | completed | Phase 1 | 45 | EMD SeronoINDUSTRY | 2 | Oct 25, 2013 | clinicaltrials |
| NCT00031681 | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00009750 | Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | unknown | Phase 1 | — | University of California, DavisOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00026377 | SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer | completed | Phase 1 | 3 | University of ChicagoOTHER | 1 | Sep 5, 2013 | clinicaltrials |
| NCT00014456 | Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 35 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Aug 28, 2013 | clinicaltrials |
| NCT00946543 | Intensity-Modulated Radiation Therapy in Treating Patients With Prostate Cancer | unknown | Phase 1 | 198 | Royal Marsden NHS Foundation TrustOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT01197209 | Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer | withdrawn | Phase 1 | 0 | Momotaro-Gene Inc.INDUSTRY | 1 | Aug 23, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Feb 10, 2015source: clinicaltrials